# RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).

> **NCT02280070** · PHASE2 · UNKNOWN · sponsor: **Clinical Research Support Center Kyush** · enrollment: 110 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **OTHER:** Laboratory test
- **OTHER:** Medical history and physical examination
- **OTHER:** BW and height
- **OTHER:** Performance status
- **OTHER:** Creatinine clearance
- **OTHER:** Biomarker
- **RADIATION:** Contrasting CT
- **OTHER:** Adverse event
- **OTHER:** HBs antigen and HCV antibody
- **OTHER:** Endoscopy
- **OTHER:** HBs antibody and HBc antibody
- **DRUG:** S-1
- **DRUG:** L-OHP (130mg/m2)
- **DRUG:** L-OHP (85 mg/m2)
- **DRUG:** l-LV
- **DRUG:** 5-FU

## Key facts

- **NCT ID:** NCT02280070
- **Lead sponsor:** Clinical Research Support Center Kyush
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-09
- **Primary completion:** 2018-08
- **Final completion:** 2020-08
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2014-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02280070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02280070, "RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02280070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*